Search results for: Multi-Indication Medicines

Educational programmes

…engage with expert-driven content. Economics of vaccines and immunisation in Sub-Saharan Africa The Economics of Vaccines and Immunisation in Africa (EVIA) – a free-to-access, fully virtual, multi-language e-learning programme. Enrol…

Turning around the NHS: Reflections on the 2025 OHE Annual Lecture

14 October 2025

…60th anniversary, we launched the Change Initiative – a multi-stakeholder international forum that brings together representatives from governments, industry, non-profits, academia and spokespeople from patient groups, civil society and much…

Patient preferences for treatment in relapsed/refractory acute leukemia

23 October 2025

…lesser degree.  Response-focused (47%) – prioritized chance of response above all else. Balanced decision-makers (32%) – considered multiple factors such as efficacy, quality of life, and duration. Convenience + efficacy focused…

Thomas Hamlyn

28 October 2025

…diseases, including his master’s dissertation which explored value-based pricing in rare diseases in the US and Germany using multi-criteria Decision analysis. Most recently he led strategic commercial analytics across the…

The case for adopting a broader perspective on value in Health Technology Assessment

3 March 2026

…humanistic spillovers. Arguably, this supports routine adoption of a broader perspective, but in the shorter-term we suggest that continuing research on a ‘multiplier’ for relative spillover effects by condition may…

World EPA Congress 2026

3 March 2026, 9:00am

World Evidence, Pricing and Access Congress is Europe’s largest conference in market access, pricing and evidence featuring 300 speakers, multiple streams and over 1500 attendees from pharma, biotech and Payers/HTAs….

Martin L. Lee

17 March 2026

…for the treatment of chronic lymphocytic leukemia, multiple myeloma, SLE, rheumatoid arthritis, Type 1 and 2 diabetes, hemophilia B and other rare bleeding disorders, and Stage 4 melanoma. He is…

Atherosclerotic cardiovascular disease (ASCVD) costs the world $680 billion a year in healthcare – roughly the size of Sweden’s entire economy, new research finds 

31 March 2026

…on country-specific data on disease burden on health expenditure.   First, they estimated the current health expenditure by multiplying country-specific estimates of per-capita health spending by population size to estimate total direct healthcare…

Two numbers, one decision: making climate-health valuation usable across sectors

18 May 2026

…derived from individuals’ willingness to pay for small reductions in the probability of sudden death, typically through wage-risk studies and stated-preference surveys. Multiplied across populations, it is what makes a…